OptiNose

$3.45
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.

$0.00 (0.00%) Today
-$0.06 (-1.71%) As of 1:00 AM UTC after-hours

Why Robinhood?

You can buy or sell OptiNose and other stocks, options, and ETFs commission-free!

About OPTN

OptiNose, Inc. operates as a pharmaceutical company. The firm engages in the development and commercialization of products for patients treated by ear, nose, throat, and allergy specialists. Its products include the XHANCE and ONZETRA Xsail. The company was founded by Per Gisle Djupesland and Helena Kyttari Djupesland in October 2000 and is headquartered in Yardley, PA. The listed name for OPTN is OptiNose, Inc. Common Stock.

CEO
Peter Kaighn Miller
Employees
204
Headquarters
Yardley, Pennsylvania
Founded
2000
Market Cap
201.72M
Price-Earnings Ratio
—
Dividend Yield
—
Average Volume
708.05K
High Today
$3.59
Low Today
$3.31
Open Price
$3.50
Volume
656.04K
52 Week High
$10.00
52 Week Low
$3.14

OPTN News

BenzingaMar 3

Recap: OptiNose Q4 Earnings

Shares of OptiNose (NASDAQ:OPTN) decreased 0.8% in pre-market trading after the company reported Q4 results. Quarterly Results Earnings per share rose 20.69%
BenzingaMar 3

OptiNose, Inc. to Host Earnings Call

NEW YORK, NY / ACCESSWIRE / March 3, 2021 / OptiNose, Inc. (NASDAQ:OPTN) will be discussing their earnings results in their 2020 Fourth Quarter Earnings call to
BenzingaMar 2

Earnings Preview for OptiNose

OptiNose (NASDAQ:OPTN) unveils its next round of earnings this Wednesday, March 03. Here is Benzinga's everything-that-matters guide for the earnings announceme

OPTN Earnings

-$0.74
-$0.64
-$0.53
-$0.43
Q2 FY19
Q3 FY19
Q4 FY19
Q1 FY20
Q2 FY20
Q3 FY20
Q4 FY20
Estimated
-$0.46 per share
Actual
-$0.46 per share
Replay Earnings Call

You May Also Like

LSXMB
All investments involve risks, including the loss of principal. Securities trading offered through Robinhood Financial LLC, a registered broker-dealer and Member SIPC. Full disclosure